Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Ovid Therapeutics (Nasdaq: OVID) announced the presentation of four posters at the 2024 American Epilepsy Society Annual Meeting in Los Angeles, highlighting their pipeline programs targeting neuronal hyperexcitability. The presentations focus on two key compounds: OV329, a next-generation GABA aminotransferase inhibitor, and OV350, a KCC2 direct activator.
The research demonstrates OV329's improved safety profile and lack of ocular accumulation compared to vigabatrin, along with its effectiveness in elevating GABA and suppressing seizures. Studies also show OV350's potential in treating nerve agent-induced benzodiazepine-resistant refractory status epilepticus. The company aims to be the first to study a KCC2 direct activator in humans next year.
Ovid Therapeutics (Nasdaq: OVID) ha annunciato la presentazione di quattro poster al 2024 American Epilepsy Society Annual Meeting a Los Angeles, mettendo in evidenza i loro programmi in fase di sviluppo mirati all'iperattività neuronale. Le presentazioni si concentrano su due composti chiave: OV329, un inibitore della GABA aminotransferasi di nuova generazione, e OV350, un attivatore diretto di KCC2.
La ricerca dimostra il profilo di sicurezza migliorato di OV329 e l'assenza di accumulo oculare rispetto al vigabatrin, insieme alla sua efficacia nell'aumentare il GABA e nel sopprimere le crisi. Gli studi mostrano anche il potenziale di OV350 nel trattamento dello stato epilettico refrattario resistente alle benzodiazepine indotto da agenti nervini. L'azienda mira a essere la prima a studiare un attivatore diretto di KCC2 sull'uomo l'anno prossimo.
Ovid Therapeutics (Nasdaq: OVID) anunció la presentación de cuatro posters en la Reunión Anual de la Sociedad Americana de Epilepsia 2024 en Los Ángeles, destacando sus programas en desarrollo dirigidos a la hiperexcitabilidad neuronal. Las presentaciones se centran en dos compuestos clave: OV329, un inhibidor de la glicina aminotransferasa de nueva generación, y OV350, un activador directo de KCC2.
La investigación demuestra el perfil de seguridad mejorado de OV329 y la falta de acumulación ocular en comparación con el vigabatrin, junto con su efectividad para elevar el GABA y suprimir las convulsiones. Los estudios también muestran el potencial de OV350 en el tratamiento del estado epiléptico refractario resistente a benzodiazepinas inducido por agentes nerviosos. La compañía aspira a ser la primera en estudiar un activador directo de KCC2 en humanos el próximo año.
Ovid Therapeutics (Nasdaq: OVID)가 로스앤젤레스에서 개최된 2024 미국 간질학회 연례 회의에서 신경 과민성에 대한 파이프라인 프로그램을 강조하는 네 개의 포스터를 발표하였다고 발표했습니다. 발표는 두 개의 주요 화합물에 초점을 맞춥니다: OV329, 차세대 GABA 아미노전이 효소 억제제, 그리고 OV350, KCC2 직접 활성화제입니다.
연구 결과 OV329는 vigabatrin에 비해 개선된 안전성 프로필과 안구 축적의 부재를 보여주며, GABA 수치를 높이고 발작을 억제하는 효과가 있음을 보여줍니다. 또한 연구들은 OV350이 신경 작용제로 인한 벤조디아제핀 내성 불응성 간질 상태 치료에 있어 잠재력을 지니고 있음을 보여줍니다. 이 회사는 내년에 사람을 대상으로 KCC2 직접 활성화제를 연구하는 첫 번째 회사가 되는 것을 목표로 하고 있습니다.
Ovid Therapeutics (Nasdaq: OVID) a annoncé la présentation de quatre affiches lors de la Réunion Annuelle de la Société Américaine de l'Épilepsie 2024 à Los Angeles, mettant en lumière ses programmes en développement ciblant l'hyperexcitabilité neuronale. Les présentations se concentrent sur deux composés clés : OV329, un inhibiteur de la GABA aminotransférase de nouvelle génération, et OV350, un activateur direct de KCC2.
La recherche démontre le profil de sécurité amélioré d'OV329 et l'absence d'accumulation oculaire par rapport au vigabatrin, ainsi que son efficacité à augmenter le GABA et à supprimer les crises. Les études montrent également le potentiel d'OV350 dans le traitement du statut épileptique réfractaire résistant aux benzodiazépines induit par des agents neurotoxiques. L'entreprise vise à être la première à étudier un activateur direct de KCC2 chez l'homme l'année prochaine.
Ovid Therapeutics (Nasdaq: OVID) gab die Präsentation von vier Postern auf dem 2024 American Epilepsy Society Annual Meeting in Los Angeles bekannt, die ihre Pipeline-Programme zur Bekämpfung der neuronalen Hypererregbarkeit hervorheben. Die Präsentationen konzentrieren sich auf zwei Schlüsselverbindungen: OV329, einen Inhibitor der GABA-Aminotransferase der nächsten Generation, und OV350, einen direkten Aktivator von KCC2.
Die Forschung zeigt das verbesserte Sicherheitsprofil von OV329 und das Fehlen von okulärer Ansammlung im Vergleich zu Vigabatrin, zusammen mit seiner Wirksamkeit bei der Erhöhung von GABA und der Unterdrückung von Anfällen. Studien zeigen auch das Potenzial von OV350 zur Behandlung des benzodiazepin-resistenten refraktären Status epilepticus, der durch Nervengifte verursacht wird. Das Unternehmen strebt an, als erstes im nächsten Jahr einen direkten KCC2-Aktivator beim Menschen zu untersuchen.
- None.
- None.
- Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin
- Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus
- A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory status epilepticus to be presented
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced it will present four posters that support the Company’s OV329 and OV350 pipeline programs for the treatment of conditions caused by neuronal hyperexcitability at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California.
“We are encouraged by the results of preclinical studies comparing OV329 to vigabatrin, which further elucidate OV329’s pharmacodynamic and safety profile, including its lack of accumulation in the brain, retina, and eye,” said Zhong Zhong, Ph.D., Chief Scientific Officer of Ovid Therapeutics. “These findings, alongside preclinical studies demonstrating rapid exposure in the brain, further support OV329’s potential to be a best-in-class GABA-aminotransferase (GABA-AT) inhibitor. GABA-AT inhibition is a proven mechanism of action, yet it has had limited clinical use over the years due to reported ocular toxicities associated with the first-generation medicine. OV329 may address the therapeutic needs of patients seeking anti-convulsant efficacy and improved safety without sedation.”
“Additionally, we are excited by new findings that reinforce OV350’s activity in terminating seizures and providing neuroprotective benefits in animals. OV350 is the first of multiple programs we are developing that directly activate the potassium chloride co-transporter 2 (KCC2), a fundamental target in restoring inhibitory/excitatory balance. Next year, we hope to be the first company to study a KCC2 direct activator in humans.”
POSTERS TO BE PRESENTED ON OVID DEVELOPMENT PROGRAMS:
OV329: A Potential Next-Generation GABA-AT Inhibitor
| Title: OV329 A Potent GABA-AT Inhibitor Does Not Accumulate in Mouse Retina: A Pharmacokinetic Study to Differentiate Eye Accumulation Between Vigabatrin Session Date & Time: 12:00-1:45 p.m. PST, Monday, December 9 Presenter: Zhong Zhong, Ph. D. Poster Number: # 3.062 | |
| Title: OV329 Rapidly Inhibits GABA-AT, Elevates Brain GABA Levels and Leads to Seizure Suppression Following IV Administration in the Rat Lithium-Pilocarpine Model of Status Epilepticus Session Date & Time: 12:00-2:00 p.m. PST, Saturday, December 7 Presenter: Julia Tsai, Ph.D. Poster Number: # 1.475 | |
| Title: Comparing the Effects of OV329 and Vigabatrin on GABA-AT Activity, and the Efficacy of Phasic And Tonic Inhibition Session Date & Time: 12:00-2:00 p.m. PST, Sunday, December 8 Presenter: Philip Colmers Ph.D. Poster Number: # 2.353 | |
OV350: A KCC2 Direct Activator
| Title: Evaluation of Anticonvulsant Efficacy of the KCC2 Activator, OV350, in a Rat Model of Nerve Agent Poisoning Session Date: 12:00-2:00 p.m. PST, Saturday, December 7 Presenter: Toshiya Nishi, DVM Poster Number: # 1.477 | |
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Forward-Looking Statements
This press release includes certain disclosures by Ovid that contain “forward-looking statements” including, without limitation: statements regarding the potential use and development of OV329, OV350 and other compounds from Ovid’s library of direct activators of KCC2, and OV888/GV101; the potential therapeutic opportunity of OV329, OV350 and other compounds from Ovid’s library of direct activators of KCC2, and OV888/GV101; OV329’s potential to be a best-in-class GABA-aminotransferase (GABA-AT) inhibitor; the expected timing of initiation of Ovid’s clinical studies; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, impediments to Ovid’s ability to achieve expected benefits of cost-savings efforts, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid’s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Contacts
Investor Relations
Garret Bonney
IR@ovidrx.com
Media
Raquel Cabo
RCabo@ovidrx.com
FAQ
What are the key findings about OV329 presented at AES 2024?
How does OV350 differ from OV329 in Ovid's pipeline?
When will Ovid present their research at the AES 2024 Annual Meeting?
What advantage does OV329 have over vigabatrin?
